Nanobiotix (NBTX) has had the highest return since January 1, 2025 by a small-cap US stock in the Biotechnology Industry, returning 861.7%.
| ASSET | % RETURN |
|---|---|
Nanobiotix (NBTX) | 861.74% |
I-Mab (IMAB) | 470.59% |
DBV Technologies (DBVT) | 382.37% |
Monopar Therapeutics (MNPR) | 358.91% |
Invivyd (IVVD) | 302.13% |
ATAI Life Sciences (ATAI) | 297.81% |
Galectin Therapeutics (GALT) | 262.6% |
Lineage Cell Therapeutics (LCTX) | 242.6% |
CytomX Therapeutics (CTMX) | 241.58% |
Editas Medicine (EDIT) | 221.26% |
Taysha Gene Therapies (TSHA) | 184.09% |
Immuneering (IMRX) | 183.64% |
Gossamer Bio (GOSS) | 180.09% |
Sana Biotechnology (SANA) | 173.01% |
Compass Therapeutics (CMPX) | 171.33% |
Stoke Therapeutics (STOK) | 168.64% |
Precigen (PGEN) | 165.83% |
Inventiva (IVA) | 152.51% |
Valneva SE ADR (VALN) | 137.02% |
AnaptysBio (ANAB) | 136.74% |
RAPT Therapeutics (RAPT) | 135.97% |
Cellectis (CLLS) | 134.27% |
Tourmaline Bio (TRML) | 133.3% |
Tango Therapeutics (TNGX) | 133.12% |
Inhibrx Biosciences (INBX) | 128.61% |
Small-cap stocks are treated as having a market cap between $300M and $2B.
